Country: Canada
Language: English
Source: Health Canada
ALPHA1-PROTEINASE INHIBITOR (HUMAN)
GRIFOLS THERAPEUTICS LLC
B02AB02
ALFA1 ANTITRYPSIN
1G
POWDER FOR SOLUTION
ALPHA1-PROTEINASE INHIBITOR (HUMAN) 1G
INTRAVENOUS
100
Schedule D
ENZYMES
Active ingredient group (AIG) number: 0120888002; AHFS:
APPROVED
2012-02-02
PRODUCT MONOGRAPH ALPHA 1 -PROTEINASE INHIBITOR (HUMAN) I.V. Injection 500, 1000 mg Alpha 1 - Antitrypsin Replenisher Manufactured by: Talecris Biotherapeutics, Inc. 8368 US 70 West Clayton, NC 27520 U.S.A. Distributed and imported by: Bayer Inc. Healthcare Division 77 Belfield Road Etobicoke, ON M9W 1G6 Canada Prepared for: Canadian Blood Services Ottawa, ON K1G 4J5 Canada Prepared for: Héma-Québec Saint-Laurent, Québec H4R 2W7 CANADA Date of Preparation: Control No. 099007 June 13, 2005 2 PRODUCT MONOGRAPH ALPHA 1 -PROTEINASE INHIBITOR (HUMAN) I.V. Injection 500, 1000 mg THERAPEUTIC CLASSIFICATION Alpha 1 - Antitrypsin Replenisher ACTION AND CLINICAL PHARMACOLOGY ALPHA 1 -PROTEINASE INHIBITOR (HUMAN) is a sterile, stable, lyophilized preparation of purified human Alpha 1 -Proteinase Inhibitor (alpha 1 -PI), also known as alpha 1 -antitrypsin. ALPHA 1 -PROTEINASE INHIBITOR (HUMAN) is intended for use in therapy of congenital alpha 1 -antitrypsin deficiency. Alpha 1 -antitrypsin deficiency is a chronic, hereditary, usually fatal, autosomal recessive disorder in which a low concentration of alpha 1 -PI (alpha 1 -antitrypsin) is associated with slowly progressive severe panacinar emphysema that most often manifests itself in the third to fourth decades of life. 2-9 [Although the terms "Alpha 1 - Proteinase Inhibitor" and "alpha 1 -antitrypsin" are used interchangeably in the scientific literature, the hereditary disorder associated with a reduction in the serum level of alpha 1 -PI is conventionally referred to as "alpha 1 -antitrypsin deficiency" while the deficient protein is referred to as “Alpha 1 -Proteinase Inhibitor” 10 ]. The emphysema is typically worse in the lower lung zones. 4,8,9 The pathogenesis of development of emphysema in alpha 1 -antitrypsin deficiency is not well understood at this time. It is believed, however, to be due to a chronic biochemical imbalance between elastase (an enzyme capable of degrading elastin tissues, released by inflammatory cells, primarily neutrophils, in the lower Read the complete document